Small molecule · Inhibitor of vascular endothelial growth factor receptor 2 (KDR) and vascular endothelial growth factor receptor 3 (FLT4) · developed by Chia Tai Tianqing Pharmaceutical Group Co.
Catequentinib (also known as anlotinib) is an oral receptor tyrosine kinase inhibitor that targets multiple receptor tyrosine kinases, including VEGFR2 and VEGFR3, to inhibit angiogenesis and tumor cell growth. It is being studied in non-small cell lung cancer and platinum-resistant recurrent clear cell ovarian cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07885709 | Phase 2 | Non-Small Cell Lung Cancer (NSCLC) | Not yet recruiting | ONC |
| NCT05130515 | Phase 2 | Platinum-resistant Recurrent Clear Cell Ovarian Cancer | Completed | ZLAB |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Non-Small Cell Lung Cancer (NSCLC)Platinum-resistant Recurrent Clear Cell Ovarian Cancer
Updated Nov 15, 2026.